Polyclonal Antibody News and Research

RSS

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.

From Rapid Novor Inc 23 Aug 2023

Potential of COVID-19 convalescent plasma for future monoclonal antibodies against severe SARS-CoV-2 inflammation

Researchers report that convalescent plasma treatment is most effective in treating hospitalized COVID-19 patients.

17 Aug 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Breakthrough: Sequencing functional antibody proteins directly from human blood

Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its REpAb® antibody discovery platform was used to successfully sequence a complex mixture of functional antibodies directly from the serum of a human patient after receiving a COVID-19 vaccine.

6 Jun 2023

Protein Medin: A new treatment target for Alzheimer's

A recent study published in the journal Nature reported the co-aggregation of medin, a fragment of lactadherin, with vascular amyloid-β in Alzheimer’s disease (AD).

10 Jan 2023

Sheep milk could be an inexpensive source of therapeutic polyclonal SARS-CoV-2 neutralizing antibodies

Researchers used sheep, a ruminant mammal, to obtain polyclonal immunoglobulins (IgGs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Dec 2022

Vaccine-induced neutralizing and non-neutralizing antibody activity against SARS-CoV-2

A new study demonstrated that vaccine-induced antibody functions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diminish with age.

7 Oct 2022

How do BNT162b2 vaccine-induced neutralizing and non-neutralizing antibodies synergize to promote protection against SARS-CoV-2?

Scientists explored the COVID-19 BNT162b2 vaccine triggered non-neutralizing and neutralizing antibody functions.

18 Aug 2022

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Researchers assess the sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage to neutralization.

9 Aug 2022

Study tests equine polyclonal antibodies against SARS-CoV-2 variants

A recent study published tested equine polyclonal antibodies against SARS-CoV-2.

8 Aug 2022

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Researchers assessed the efficacy of the novel SARS-CoV-2 doggybone deoxyribonucleic acid (DNA) vaccine.

13 Jul 2022

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

A recent study published in the journal Antiviral Research explored alternative sources of polyclonal antibodies against SARS-CoV-2, which would be more cost-effective, amendable to regulatory approval, and widespread use.

12 May 2022

Study describes ultra-structure of Nipah virus surface glycoprotein

A team of US-based scientists has recently demonstrated the cryo-electron microscopic structure and antigenicity of the attachment glycoprotein of the Nipah virus.

27 Apr 2022

Role of natural immunity to SARS-CoV-2 on post-vaccination antibody responses in staff and residents of long-term care facilities

A new study collected and analyzed sera from the staff at a local long-term care facility from August to December 2020, where an outbreak occurred in September 2020.

8 Apr 2022

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

A new study evaluated the specificity of antibody response elicited by the Delta variant of SARS-CoV-2.

18 Mar 2022

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

In a new study, a team of researchers assessed the neutralizing activity of XAV-19, a glyco-humanized polyclonal antibody derived from hyperimmunized animal hosts, against the SARS-CoV-2 Omicron variant.

1 Feb 2022

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

In a new study, researchers assessed the sera from COVID-19 infected and vaccinated individuals against the receptor-binding domain in the spike protein of the SARS-CoV-2 wildtype virus and its variants.

13 Jan 2022